Welcome to our dedicated page for Seer SEC filings (Ticker: SEER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Seer, Inc. (Nasdaq: SEER) SEC filings page provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Seer’s capital structure, governance, and financial reporting practices as a life sciences company focused on deep, unbiased proteomics.
Recent Form 8-K filings include current reports on quarterly financial results, where Seer furnishes press releases describing revenue from Proteograph instruments, consumable kits, and Technology Access Center service projects. Other 8-Ks address corporate governance matters such as the election of directors, ratification of the independent registered public accounting firm, and notices related to Nasdaq listing rule compliance, including audit committee composition.
Seer’s filings also document important changes to its equity structure. A December 2025 Form 8-K describes the automatic conversion of all outstanding Class B common stock into Class A common stock pursuant to the company’s Amended and Restated Certificate of Incorporation, the subsequent retirement of the Class B shares, and the filing of a Certificate of Retirement in Delaware. The filing explains how this conversion affected voting power while leaving economic interests unchanged, and confirms that Seer’s Class A common stock continues to trade on The Nasdaq Global Select Market under the SEER ticker.
On Stock Titan, Seer’s SEC filings are updated as they are made available through EDGAR, and AI-powered summaries can help explain the key points of complex documents. Users can quickly identify items related to financial results, stock structure changes, governance decisions, and listing status, and then drill into the full filings for deeper review. This makes it easier to understand how Seer reports on its Proteograph-focused business and its obligations as a Nasdaq-listed issuer.
Seer, Inc. disclosed that it has received a highly contingent, non-binding and unsolicited proposal from the Radoff-JEC Group to acquire all outstanding shares of Seer’s Class A common stock for $2.25 per share in cash plus a contingent value right. The Board, with independent financial and legal advisors, will carefully review the proposal to decide what is in the best interests of the company and its stockholders. In parallel, the Radoff-JEC Group has nominated three director candidates for election at Seer’s 2026 Annual Meeting. Seer’s Corporate Governance and Nominating Committee will evaluate these nominees under the company’s bylaws, and the Board will provide its recommendation in a future definitive proxy statement. The company emphasized that no stockholder action is required at this time and plans to send a BLUE proxy card with its 2026 proxy materials.
Seer, Inc. received an amended Schedule 13D from a group led by Bradley Radoff and Michael Torok outlining an unsolicited takeover proposal and board contest. The group and related entities report beneficial ownership stakes ranging from 0.4% to 4.6% of Seer’s Class A common stock.
On April 13, 2026, the reporting persons submitted a non-binding proposal to acquire 100% of Seer’s equity for $2.25 per share in cash, a stated 33% premium to the most recent closing price, plus a contingent value right giving stockholders 80% of net proceeds from any sale or license of Seer’s business and assets, including PrognomiQ. The proposal assumes at least $215 million of net cash and cash equivalents at closing and is not subject to financing conditions.
The group asked Seer’s board to respond to the proposal by 5:00 p.m. ET on April 22, 2026, after which it would expire. Radoff also nominated Howard H. Berman, Joshua S. Horowitz and Luis E. Rinaldini to Seer’s board for the 2026 annual meeting and the group entered into an amended and restated group agreement covering joint filings, proxy solicitation efforts and trading restrictions while Seer’s tax benefit preservation plan (the “NOL Pill”) remains in effect.
Seer, Inc. reported that the U.S. Patent Trial and Appeal Board issued a Final Written Decision in an inter partes review of U.S. Patent No. 11,435,360 B2 covering Seer’s nanoparticle-based protein enrichment technology for its Proteograph product suite.
The PTAB found that petitioners PreOmics GmbH and Biognosys AG failed to show unpatentability of certain challenged claims, leaving a total of 23 patent claims, including five challenged and 18 unchallenged, valid and enforceable. Other challenged claims were found unpatentable. The upheld claims relate to detecting proteins across a wide concentration range and to particle aspects of the technology, which support deep proteomic analysis. Either side may appeal by filing a notice of appeal by May 25, 2026.
Seer, Inc. amended its Tax Benefit Preservation Plan to clarify the definition of “Beneficial Ownership” and its interaction with Treasury Regulation § 1.382-3(a)(1). The change follows a Delaware Court of Chancery stockholder action challenging the original definition. To resolve the matter and moot the claims, Seer agreed to this amendment and to pay plaintiff’s counsel a $250,000 mootness fee, which will fully satisfy any related claims for attorneys’ fees, costs, and expenses.
Seer, Inc. investors led by Bradley Radoff and Michael Torok have updated their Schedule 13D to detail a significant activist stake and challenge a new tax benefits preservation plan. The group now reports beneficial ownership of 4,277,528 Class A shares, representing approximately 7.6% of Seer’s 56,219,599 shares outstanding as of December 31, 2025.
The filing breaks out ownership across several entities. Bradley Radoff is deemed to beneficially own 2,610,232 shares, or about 4.6% of the company, including 500,000 shares held by the Radoff Family Foundation. Michael Torok is deemed to beneficially own 1,667,296 shares, or about 3.0%, including shares held through JEC II Associates, LLC and The MOS Trust.
The investors express strong concern with the board’s adoption of a tax benefits preservation plan on February 26, 2026, which limits additional ownership to 4.9%. They argue this measure may discourage shareholders from building larger positions in advance of any potential proxy contest and call on the board to justify the plan’s necessity and impact on stockholder rights.
Seer, Inc. files its annual report describing a fast-growing proteomics tools business built around its Proteograph Product Suite. The platform combines proprietary nanoparticles, automation (the SP200 instrument) and cloud software to deliver deep, unbiased proteomic data at peptide-level resolution.
In 2025 Seer launched its next-generation Proteograph ONE assay and SP200 automation, boosting throughput roughly tenfold versus its original assay to more than 1,000 samples per week. The company reports more than 190 customers in over 20 countries and cites around 70 third-party publications using its technology as of December 31, 2025.
Seer targets a roughly $30 billion proteomics market and positions its data-rich workflows as a foundation for population-scale studies and AI-driven biology. As of June 30, 2025, non-affiliate equity market value was about $113.8 million, and 56,420,772 Class A shares were outstanding as of February 23, 2026.
Seer, Inc. adopted a Tax Benefit Preservation Plan designed to protect its net operating losses and other tax attributes. The Board declared a dividend of one right for each outstanding share of Class A common stock to stockholders of record on March 9, 2026.
Each right allows the holder to purchase one one-thousandth of a share of Series A Participating Preferred Stock at an exercise price of $11.00. The plan is triggered if any person or group acquires 4.9% or more of Seer’s common stock without Board approval, creating significant dilution for the acquiror.
The rights are redeemable by the company for $0.001 per right and can be exchanged for common stock at one share per right in certain circumstances. The plan generally expires on February 25, 2029, but will terminate earlier if stockholders do not ratify it by February 25, 2027 or if the Board determines it is no longer needed to protect tax benefits.
Seer, Inc. reported modest growth but continued losses for the fourth quarter and full year 2025. Fourth quarter revenue was $4.2 million, up 5% from $4.0 million, with gross margin of 52% and operating expenses reduced to $19.6 million. Net loss improved to $16.0 million from $21.7 million.
For full year 2025, revenue reached $16.6 million, a 17% increase from $14.2 million, and gross margin was 51%. Operating expenses fell 19% to $86.5 million, narrowing the net loss to $73.6 million from $86.6 million. Seer ended the year with $240.6 million in cash, cash equivalents and investments and an installed base of 82 Proteograph instruments.
For 2026, Seer expects revenue between $16 million and $18 million, implying approximately 3% growth at the midpoint, signaling a cautious outlook as it continues investing while operating at a loss.
Seer, Inc. shareholders led by Bradley Radoff and Michael Torok have filed a Schedule 13D disclosing an activist stake of 3,650,000 Class A shares, or about 6.5% of shares outstanding. The group, which includes the Radoff Family Foundation, JEC II Associates, The MOS Trust and MOS PTC, reports significant open-market purchases funded with working capital and personal funds.
The investors state they bought Seer shares because they believed they were undervalued and represented an attractive opportunity. They are engaging with Seer’s board and management on ways to enhance stockholder value, including a potential strategic review, changes to board composition, and possible changes to capital allocation or ownership structure, including a sale of the company in whole or in parts. A Group Agreement dated February 20, 2026 coordinates their activities and shares related expenses between Radoff and JEC based on their respective holdings.